Targeting New Pathways to Improve Outcomes in Renal Cell Carcinoma Building on recent success requires intervention at multiple steps in the cancer immunity cycle Nov 14, 2023
No Boost in Outcomes for Clear Cell RCC With Higher Belzutifan Dose A quarter of patients responded whether at the recommended or higher dose Nov 13, 2023
Tyrosine Kinase Inhibitor Active in Heavily Treated Renal Cell Carcinoma Responses to "special drug" zanzalintinib in cabozantinib-exposed and unexposed patients Nov 11, 2023
Randomized Trial Backs HIF-2a Inhibition in Advanced RCC After immunotherapy-TKI failure, belzutifan produces better outcomes versus everolimus Oct 24, 2023
SABR Offers New Hope for Older Patients With Inoperable Kidney Cancer Phase II study shows 100% local control and cancer-specific survival after more than 3 years Oct 01, 2023
Adjuvant Everolimus Falls Short in High-Risk Renal Cancer However, the drug did show benefit in a subgroup at highest risk of recurrence after nephrectomy Jul 31, 2023
Upfront Systemic Therapy, Deferred Surgery Pass Muster in Advanced Kidney Cancer Two studies suggest no harm from deferred cytoreduction, potential benefits of immunotherapy May 02, 2023
CAR T-Cell Therapy Shows Promise in Advanced Kidney Cancer ORR of 30% in patients with CD70-positive disease using off-the-shelf, allogeneic product Apr 19, 2023
Post-Immunotherapy Combo Promising in Advanced RCC Duration of response reaches 18.6 months with belzutifan plus cabozantinib Apr 03, 2023
Novel PET Imaging Agent Accurately IDs Clear Cell Renal Cancers ZIRCON trial meets sensitivity and specificity targets Mar 13, 2023
Combo Falters in Papillary Renal Cancer, but Some Promise in MET-Driven Subset Over 50% of patients with advanced MET-driven tumors responded to savolitinib plus durvalumab Feb 24, 2023
ICI/TKI Combo Maintains Survival Benefit in Advanced RCC Updated trial data show nivolumab/cabozantinib doublet "is getting better with age" Feb 20, 2023
Pre-Op Axitinib Helps for Partial Nephrectomy of Complex Renal Tumors Approach in small ongoing trial resulted in reduction in tumor size and complexity Dec 02, 2022
Allogeneic CAR T-Cell Therapy Shows Early Promise in Kidney Cancer CTX130 yields sustained complete response in one patient with relapsed/refractory disease Nov 15, 2022
Role of Cytoreductive Nephrectomy Unclear for Dedifferentiated Kidney Cancer Thirteen-month survival gain falls short of statistical significance in observational study Nov 10, 2022
Immune Stimulator May Enhance Targeted Therapy's Activity in Metastatic RCC Numerical advantage in median survival, response rate, durability with dendritic-cell agent Nov 09, 2022
Immunotherapy Doublet Shows Promise for Nonsurgical Control of Small Kidney Cancers Nivolumab/ipilimumab achieves 1-year PFS of 100% in unresectable T1N0M0 tumors Nov 07, 2022
Probiotic May Rev Up Response to Immunotherapy in Advanced Kidney Cancer Dramatic slowing of disease progression, prolonged responses with microbiome modulator Nov 06, 2022
Triplet in First-Line Kidney Cancer Thwarts Disease Progression Randomized study shows "clinically meaningful" PFS improvement over dual immunotherapy alone Sep 13, 2022
Three Adjuvant Immunotherapy Trials Flop in Renal Cell Carcinoma Studies appear to contradict benefit previously shown with pembrolizumab in this setting Sep 12, 2022
Fewer Complications With Robotic Nephrectomy in Complex Kidney Tumors However, trial comparing robotic and open surgery was stopped early due to low enrollment Jul 06, 2022
Oral Retinoid May Ease Painful Skin Reactions to Anticancer Therapy Preliminary data on acitretin therapy are promising May 11, 2022
Check Troponin in RCC Patients Before Checkpoint-VEGFR Inhibitor Combo In JAVELIN Renal 101, those with high levels had more heart events with avelumab-axitinib Mar 05, 2022
FDA OKs PD-1 Inhibitor for Adjuvant Treatment of Kidney Cancer Key trial showed 32% reduction in risk of recurrence with pembrolizumab Nov 18, 2021
Cabozantinib Shows Activity Against RCC Brain Metastases Retrospective study reported intracranial responses in about one half of patients Oct 22, 2021
'A Quantum Leap Forward': Potential New Standard in High-Risk RCC Adjuvant immunotherapy led to 32% reduction in the risk of recurrence, positive trend in OS Jun 03, 2021
A CLEAR Upfront Winner in Advanced RCC? Pembrolizumab-lenvatinib makes splash with longest PFS benefit in RCC recorded to date Feb 14, 2021
Practice-Changing Trial in Metastatic Papillary RCC Cabozantinib improved PFS, response rates over sunitinib Feb 14, 2021
Another First-Line Combo Succeeds in Advanced RCC Third immunotherapy plus TKI combination tops sunitinib Sep 19, 2020
Olympic Ice Dancer's Renal Cell Carcinoma Maia Shibutani is "embracing the moment" and raising money for healthcare workers Sep 10, 2020
Cancer Immunotherapy Tied to Severe COVID-19 Outcomes Nearly threefold increased risk of hospitalization, severe respiratory illness Jun 25, 2020
6-Week Keytruda Safe, Effective in Melanoma Schedule gets FDA approval for all adult indications Apr 30, 2020
DOAC Works in Cancer-Related VTE, No Tradeoff in Bleeds Apixaban monotherapy matches dalteparin in non-inferiority trial Mar 29, 2020
Are Low-Density Incidental Renal Masses Being Misdiagnosed? New study raises concerns about criteria for benign cysts vs aggressive renal cancer Dec 23, 2019
Metastatic Renal Cell Carcinoma: Watch for Brain Mets Present in roughly 5% of patients, survival worse in patients with larger or more lesions Nov 18, 2019
Long-Term Surveillance Safe for Small Renal Tumors Two cases of metastasis, one cancer death after almost 5 years of follow-up Jun 13, 2019
Surgery Delay OK for Most With Renal Cell Carcinoma Two studies add support for active surveillance for small tumors May 08, 2019
Do Keloids Convey a Higher Cancer Risk? Taiwanese researchers show association between raised scars and cancers Mar 03, 2019
No Survival Bump Yet with Tivozanib for RCC Selected studies on kidney cancer from the Genitourinary Cancers Symposium Feb 18, 2019
